Enliven Therapeutics Inc ELVN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
-
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
-
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Enliven Shares Climb on Positive Leukemia Drug Trial Data
-
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
-
Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
-
Enliven Therapeutics to Present at Upcoming Investor Conferences
-
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
Trading Information
- Previous Close Price
- $50.87
- Day Range
- $50.27–52.18
- 52-Week Range
- $14.79–52.39
- Bid/Ask
- $51.35 / $52.40
- Shares Outstanding
- 71.44M
- Market Cap
- $3.70B
- Volume/Avg
- 749,919 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 61
Valuation
|
Metric
|
ELVN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.95 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ELVN
|
|---|---|
Quick Ratio | 39.38 |
Current Ratio | 40.32 |
Interest Coverage | — |
Quick Ratio
ELVN
Profitability
|
Metric
|
ELVN
|
|---|---|
Return on Assets (Normalized) | −14.33% |
Return on Equity (Normalized) | −14.81% |
Return on Invested Capital (Normalized) | −18.72% |
Return on Assets
ELVN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|WT&<nB@ | LOCK|!^y< | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@St>q% | LOCK|xRb@< | $69B | |||
| argenx SE ADR
ARGX
| LOCK|DHh<@^ | LOCK|nj | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|p%YSVlC | LOCK|G^bf^ | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$%&v^^ | LOCK|#F | $36B | |||
| Moderna Inc
MRNA
| LOCK|!W<j&B | LOCK|>^% | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$y$&ZnD^ | LOCK|V#LC | $25B | |||
| Incyte Corp
INCY
| LOCK|$Y>HwvR | LOCK|Lj< | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|ZfkM&^! | LOCK|MrH | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|V#K@mKz | LOCK|kY | $16B |
United States